Evaluation Using ClearView in Determining Association to the Cardiac Risk Factors
| Status: | Completed |
|---|---|
| Conditions: | Peripheral Vascular Disease, Cardiology |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 18 - 85 |
| Updated: | 5/27/2013 |
| Start Date: | November 2012 |
| End Date: | April 2013 |
| Contact: | Josh Sugino |
| Email: | jsugino@mimg.com |
| Phone: | 949-364-6000 |
Evaluation Using ClearView in Determining Association to the Cardiac Risk Factors (Cardiac-CV)
The objective of this study is to explore the relationship between the ClearView scan
results and a variety of cardiovascular risk indicators such as the Coronary Calcium Score,
Framingham Risk Factors, Reynolds Risk Score, and biomarkers of inflammation. The ClearView
device is a bio-electrographic tool that may assist medical professionals in rapid
assessment of the systemic origin of the patient's presenting symptom(s). The ClearView is a
potentially valuable resource that may benefit a physician's office by offering expedited
differentiation capabilities. The subsequent results have the potential to include more
data that would allow rapid patient diagnosis, triage, and treatment; optimized precious
resource expenditure (nursing, physician, etc.); lower costs to facility, patient and
insurance company; and decreased office wait time.
Inclusion Criteria:
- Sex: Male or Female
- Age range: 18 to 85
- Patients who are recommended for and who have had a cardiac CT study that produces a
Coronary Calcium Score within 30 days prior to the ClearView Scan or plan to have the
CT within 14 days after the ClearView Scan.
- Patients who have had a blood test resulting in hs-CRP, fasting lipid panel and MPO
results within 6 months prior to the ClearView Scan or plan to have the tests done
within 14 days after the ClearView Scan.
- The patient or legal representative is able to understand and provide signed consent
for the procedure.
Exclusion Criteria:
- Patients with pacemakers or another implanted electrical device, such as an automatic
internal cardiac defibrillator.
- Patients connected to an electrical device that cannot be removed or temporarily
powered off (i.e. monitor) during subject testing with the ClearView Device
- Vulnerable populations
- Patients actively being treated for cancer or with a previous diagnosis of
cancer that required chemotherapy, radiation therapy or hormonal therapy.
- Patients missing all or any part of a fingertip (excluding fingernail).
- Patients with involuntary hand tremors /shaking of the hands that may prevent
clear imaging.
We found this trial at
1
site
Click here to add this to my saved trials
